Inmune Bio (INMB) Common Equity (2017 - 2025)
Historic Common Equity for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $25.4 million.
- Inmune Bio's Common Equity fell 3438.14% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year decrease of 3438.14%. This contributed to the annual value of $32.1 million for FY2024, which is 1404.12% down from last year.
- According to the latest figures from Q3 2025, Inmune Bio's Common Equity is $25.4 million, which was down 3438.14% from $28.9 million recorded in Q2 2025.
- In the past 5 years, Inmune Bio's Common Equity ranged from a high of $88.3 million in Q3 2021 and a low of $25.4 million during Q3 2025
- Moreover, its 5-year median value for Common Equity was $43.9 million (2023), whereas its average is $50.1 million.
- As far as peak fluctuations go, Inmune Bio's Common Equity skyrocketed by 18365.76% in 2021, and later tumbled by 4895.83% in 2024.
- Over the past 5 years, Inmune Bio's Common Equity (Quarter) stood at $80.2 million in 2021, then dropped by 25.08% to $60.1 million in 2022, then crashed by 37.87% to $37.3 million in 2023, then dropped by 14.04% to $32.1 million in 2024, then fell by 20.93% to $25.4 million in 2025.
- Its last three reported values are $25.4 million in Q3 2025, $28.9 million for Q2 2025, and $29.7 million during Q1 2025.